JAMA stirred up more controversy yesterday. Now, Naprosyn is the safest NSAID. Diclofenac (Voltaren) is now on notice. It seems the studies continue to show differing results.
What does this mean? For Merck, it’s more bad news. Their new COX-2, Arcoxia, was touted to have a similar cardiovascular event rate with diclofenac. Now it looks like they chose the wrong NSAID to compare it with.
Good luck getting Arcoxia approved now.
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
